TTelix· Business · 13 sources · 6dStoryTelix agrees to acquire ITM for $1.65 billion upfrontTelix agreed to acquire ITM for US$1.65 billion upfront, plus up to US$700 million in ITM-11 milestones, in a share-heavy deal aiming to close by end of FY2026.Business· 6d
TTelix· Business · 9 sources · Sep 2, 2026StoryTelix completes BiPASS trial enrollment, aligns with FDA on NDA pathTelix has completed enrollment of 350 patients in its Phase 3 BiPASS trial evaluating Ga-68 PSMA-PET plus MRI for pre-biopsy prostate cancer detection, with the aim of improving diagnostic accuracy and reducing unnecessary biopsies. The company also aligned with the FDA on a New Drug Application pathway that could support reimbursement and broaden patient access if approved, a development that sparked investor interest.Business· Sep 2, 2026
